Atacicept 150 mg

DRUG5 trials

Sponsors

EMD Serono, Vera Therapeutics, Inc.

Conditions

Berger DiseaseIgA Nephropathy (IgAN)Lupus Erythematosus, SystemicRelapsing Multiple SclerosisRenal and Urinary Disorders

Phase 2

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

CompletedNCT00624338

EMD SeronoLupus Erythematosus, Systemic

Start: 2008-01-31End: 2012-10-31Updated: 2016-03-14

Atacicept in Multiple Sclerosis Extension Study, Phase II

TerminatedNCT00853762

EMD SeronoRelapsing Multiple Sclerosis

Start: 2009-03-31End: 2011-02-28Updated: 2017-03-20

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

CompletedNCT01972568

EMD SeronoLupus Erythematosus, Systemic

Start: 2013-12-31End: 2016-09-30Updated: 2018-01-02

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

TerminatedNCT02070978

EMD SeronoLupus Erythematosus, Systemic

Start: 2014-07-29End: 2018-02-09Updated: 2019-03-21

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Enrolling by invitationNCT06674577

Vera Therapeutics, Inc.Berger Disease, IgA Nephropathy (IgAN), Renal and Urinary Disorders

Start: 2024-12-01End: 2031-05-21Target: 750Updated: 2026-06-22

Related Papers

Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus

Lara D. Veeken2021-02-0424 citations

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study

Lara D. Veeken2020-01-2048 citations

S7A:4 Reduction of systemic lupus flares by atacicept in a randomised, placebo-controlled, phase iib study (address ii) and its extension study

2018-03-01

S7A:5 Sri response, attainment of low disease activity and safety in patients with systemic lupus treated with atacicept in a phase iib study (address ii)

2018-03-01

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.

2018-02-01177 citations

8 Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24-week randomisedrandomized, placebo-controlled, phase iib study

2017-03-012 citations

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

2014-06-20224 citations

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

2014-03-06250 citations